Background: Metastatic/unresectable angiosarcoma (AS) is a disease with poor prognosis. Median survival is generally less than 12 months. Single agent taxane or anthracycline are commonly used agents. However optimal 1st line systemic treatment remains to be defined.

Method: We undertook a retrospective chart review of AS pts seen in 8 sarcoma academic centres across Asia. Pt with complete clinical, treatment and follow-up data were enrolled.

Results: 271 metastatic/unresectable AS pts were included into this study. Median age was 64 yrs. 64% of pts presented with metastatic/unresectable disease at time of initial diagnosis while 36% developed metastatic disease at a median of 7.6 months following initial diagnosis. Primary origin of tumor was from a cutaneous site in 55% vs a visceral site in 45% of pts; the most common visceral site being the liver. 52% of these pts received systemic chemotherapy, of whom 55%, 25% and 20% of these pts received 1 line, 2 lines and >3 lines of chemotherapy respectively. Of pts who received systemic chemotherapy, the most common 1st line regimen used was paclitaxel in 47% and liposomal doxorubicin in 19%. At a median follow-up of 7.2 months after diagnosis of metastatic/unresectable disease, overall survival (OS) was 8.3 months, 11.5 months in those who received at least 1 line of palliative chemotherapy vs 4.4 months (p < 0.01) in those who did not receive palliative chemotherapy. Comparing between pts who received single agent paclitaxel vs anthracycline, progression-free survival (PFS) as defined by investigator was 4.7 months for paclitaxel vs 2.8 months for anthracycline (HR = 0.75, p = 0.2). Notably PFS in 1st line chemotherapy and OS were not significantly different between pts whose tumors developed from a primary cutaneous vs visceral site, (PFS: 3.8 months vs 3.2 months (HR = 0.87, p = 0.4); OS: 12.1 months vs 9.5 months (HR = 0.96, p = 0.8)). Evaluation of prognostic factors in this cohort of pts would be presented subsequently.

Conclusions: This study confirms the poor prognosis of pts with metastatic/unresectable angiosarcoma AS. First line treatment with single agent taxane or anthracycline appears comparable.

Legal entity responsible for the study: National Cancer Centre Singapore

Funding: N/A

Disclosure: V. Sriuranpong. Corporate sponsored research: Novartis, MSD, Astra Zeneca, Roche, Lilly, Sanofi, Pfizer, BMS. R. Quek: Grants/research support: Novartis, Pfizer, Janssen, Bayer and Eisai Honoraria or consultation fees: Novartis, Bayer, BMS, Merck, Roche and Eisai Participation in a company sponsored speaker’s bureau: Novartis, Bayer, Merck and Eisai. All other authors have declared no conflicts of interest.